If the drug is more broadly used in people with obesity and not just diabetes, those with higher body weights may see even ...

Thousand Oaks, California Wednesday, June 25, 2025, 13:00 Hrs [IST] ...

Researchers found that once-monthly maridebart cafraglutide led to substantial weight loss and improved glycemic control in ...

A new monthly weight loss drug, MariTide, helped people shed up to 20% of body weight in a Phase 2 trial—comparable to Wegovy ...

An experimental obesity drug has shown it can “substantially” reduce weight within a year, offering new hope for people with ...

Amgen's MariTide showed strong weight loss and metabolic gains in Phase 2, with no new safety signals as Phase 3 trials begin in obesity and T2D.

Amgen Inc. (NASDAQ:AMGN) is one of the These 10 Stocks Took A Shocking Fall. Amgen Inc. extended its losing streak to a ...

Full Phase 2 study results showed side effects that led people to stop treatment with MariTide, as well as weight loss ...

The renowned health and wellness platform, Hims & Hers Health, Inc. HIMS, has increasingly prioritized weight loss as a key area of growth and innovation in its healthcare platform. In recent months, ...

NVO ends its deal with HIMS over safety concerns tied to compounded Wegovy, hitting patient access and market share plans.

Trial finds weight loss drug taken monthly helps people lose 20% of body weight - The new drug may rival other weight loss ...

A new trial has found that a weight loss drug taken monthly helps people to lose 20 percent of their body weight. Other weight loss medications such as Ozempic, Wegovy and Mounjaro have become popular ...